Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis

References

• Ilangavan K, Kalu E. High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners. Fertil Steril. 2010 Feb;93(3):e10; author reply e12. PubMed PMID: 20036358.
   Google Scholar
• Agarwal SK, Chapron C, Giudice LC, et al. Clinical diagnosis of endometriosis: a call to action. Am J Obstet Gynecol. 2019;220(4):354.e1‐354.e12.
   Google Scholar
• Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update. 2009 Jul-Aug;15(4):441–461. PubMed PMID: 19279046.
   Google Scholar
• Barra F, Grandi G, Tantari M, et al. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments. Expert Opin Biol Ther. 2019 Apr;19(4):343–360. PubMed PMID: 30763525.
   Google Scholar
• Barra F, Scala C, Mais V, et al. Investigational drugs for the treatment of endometriosis, an update on recent developments. Expert Opin Investig Drugs. 2018 May;27(5):445–458. PubMed PMID: 29708812.
   Google Scholar
• Vercellini P, Somigliana E, Vigano P, et al. Endometriosis: current therapies and new pharmacological developments. Drugs. 2009;69(6):649–675. PubMed PMID: 19405548.
   Google Scholar
• Berlanda N, Somigliana E, Vigano P, et al. Safety of medical treatments for endometriosis. Expert Opin Drug Saf. 2016 Jan;15(1):21–30. PubMed PMID: 26576479.
   Google Scholar
• Grandi G, Barra F, Ferrero S, et al. Hormonal contraception in women with endometriosis: a systematic review. Eur J Contracept Reprod Health Care. 2019 Feb;24(1):61–70. PubMed PMID: 30664383.
   Google Scholar
• Jensen JT, Schlaff W, Gordon K. Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence. Fertil Steril. 2018 Jul 1;110(1):137–152 e1. PubMed PMID: 29937152.
   Google Scholar
• Lidegaard O, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: danish cohort study, 2001–9. BMJ. 2011 Oct 25;343(oct25 4):d6423. PubMed PMID: 22027398; PubMed Central PMCID: PMCPMC3202015.
   Google Scholar
• Harada T, Momoeda M, Taketani Y, et al. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril. 2008 Nov;90(5):1583–1588. PubMed PMID: 18164001.
   Google Scholar
• Harada T, Kosaka S, Elliesen J, et al. Ethinylestradiol 20 mug/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial. Fertil Steril. 2017 Nov;108(5):798–805. PubMed PMID: 28911925.
   Google Scholar
• Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil Steril. 2017 Mar;107(3):533–536. PubMed PMID: 28162779.
   Google Scholar
• Barra F, Scala C, Ferrero S. Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis. Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):399–415. PubMed PMID: 29617576.
   Google Scholar
• Morotti M, Remorgida V, Venturini PL, et al. Progestogen-only contraceptive pill compared with combined oral contraceptive in the treatment of pain symptoms caused by endometriosis in patients with migraine without aura. Eur J Obstet Gynecol Reprod Biol. 2014 Aug;179:63–68. PubMed PMID: 24965982.
   Google Scholar
• Buggio L, Somigliana E, Barbara G, et al. Oral and depot progestin therapy for endometriosis: towards a personalized medicine. Expert Opin Pharmacother. 2017 Oct;18(15):1569–1581. PubMed PMID: 28914561.
   Google Scholar
• Morotti M, Sozzi F, Remorgida V, et al. Dienogest in women with persistent endometriosis-related pelvic pain during norethisterone acetate treatment. Eur J Obstet Gynecol Reprod Biol. 2014 Dec;183:188–192. PubMed PMID: 25461377.
   Google Scholar
• Strowitzki T, Faustmann T, Gerlinger C, et al. Safety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program. Int J Womens Health. 2015;7:393–401. PubMed PMID: 25926759; PubMed Central PMCID: PMCPMC4403681.
   Google Scholar
• Ferrero S, Gillott DJ. Venturini PLet al. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reprod Biol Endocrinol. 2011 Jun 21;9:89.
   Google Scholar
• Leone Roberti Maggiore U, Scala C, Remorgida V, et al. Triptorelin for the treatment of endometriosis. Expert Opin Pharmacother. 2014 Jun;15(8):1153–1179. PubMed PMID: 24832495.
   Google Scholar
• Ferrero S, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. Expert Opin Pharmacother. 2018 Jul;19(10):1109–1125. PubMed PMID: 29975553.
   Google Scholar
• Levine D, Kaufman L, Cuenca VG, et al. Cell growth effects of leuprolide on cultured endometrioma cells. J Reprod Med. 2007 Jul;52(7):581–584. PubMed PMID: 17847754.
   Google Scholar
• Fedele L, Bianchi S, Bocciolone L, et al. Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study. Fertil Steril. 1993 Mar;59(3):516–521. PubMed PMID: 8458450.
   Google Scholar
• Bergqvist A, Bergh T, Hogstrom L, et al. Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertil Steril. 1998 Apr;69(4):702–708. PubMed PMID: 9548161.
   Google Scholar
• Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron study group. Fertil Steril. 1990 Sep;54(3):419–427. PubMed PMID: 2118858.
   Google Scholar
• Miller JD. Leuprolide acetate for the treatment of endometriosis. Prog Clin Biol Res. 1990;323:337–341. PubMed PMID: 2106145.
   Google Scholar
• Miller JD. Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: a double-blind, randomized, placebo-controlled trial. Am J Obstet Gynecol. 2000 Jun;182(6):1483–1488. PubMed PMID: 10871469.
   Google Scholar
• Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2010;8(12):CD008475. PubMed PMID: 21154398.
   Google Scholar
• Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril. 2006 Feb;85(2):314–325. PubMed PMID: 16595206.
   Google Scholar
• Crosignani PG, Luciano A, Ray A, et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod. 2006 Jan;21(1):248–256. PubMed PMID: 16176939.
   Google Scholar
• Harada T, Momoeda M, Taketani Y, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis–a randomized, double-blind, multicenter, controlled trial. Fertil Steril. 2009 Mar;91(3):675–681. PubMed PMID: 18653184.
   Google Scholar
• Strowitzki T, Marr J, Gerlinger C, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010 Mar;25(3):633–641. PubMed PMID: 20089522.
   Google Scholar
• Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod. 2005;20(7):1993–1998.
   Google Scholar
• Ferreira RA, Vieira CS, Rosa ESJC, et al. Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. Contraception. 2010 Feb;81(2):117–122. PubMed PMID: 20103448.
   Google Scholar
• Bayoglu Tekin Y, Dilbaz B, Altinbas SK, et al. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril. 2011 Feb;95(2):492–496. PubMed PMID: 20883991.
   Google Scholar
• Vercellini P, Trespidi L, Colombo A, et al. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril. 1993 Jul;60(1):75–79. PubMed PMID: 8513962.
   Google Scholar
• Parazzini F, Di Cintio E, Chatenoud L, et al. Estroprogestin vs. gonadotrophin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: a randomized trial. Gruppo Italiano per lo studio dell’Endometriosi. Eur J Obstet Gynecol Reprod Biol. 2000 Jan;88(1):11–14. PubMed PMID: 10659911.
   Google Scholar
• Guzick DS, Huang LS, Broadman BA, et al. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril. 2011 Apr;95(5):1568–1573. PubMed PMID: 21300339; PubMed Central PMCID: PMCPMC4271794.
   Google Scholar
• Soysal S, Soysal ME, Ozer S, et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod. 2004 Jan;19(1):160–167. PubMed PMID: 14688176.
   Google Scholar
• Lemay A, Maheux R, Huot C, et al. Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. Am J Obstet Gynecol. 1988 Feb;158(2):233–236. PubMed PMID: 3124618.
   Google Scholar
• Dmowski WP, Radwanska E, Binor Z, et al. Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertil Steril. 1989 Mar;51(3):395–400. PubMed PMID: 2493400.
   Google Scholar
• Dawood MY, Spellacy WN, Dmowski WP, et al. A comparison of the efficacy and safety of buserelin vs danazol in the treatment of endometriosis. Protocol 310 Study Group. Prog Clin Biol Res. 1990;323:253–267. PubMed PMID: 2106142.
   Google Scholar
• Agarwal SK, Hamrang C, Henzl MR, et al. Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin study group. J Reprod Med. 1997 Jul;42(7):413–423. PubMed PMID: 9252932.
   Google Scholar
• Hornstein MD, Yuzpe AA, Burry KA, et al. Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertil Steril. 1995 May;63(5):955–962. PubMed PMID: 7720940.
   Google Scholar
• Kumar P, Sharma A. Gonadotropin-releasing hormone analogs: understanding advantages and limitations. J Hum Reprod Sci. 2014 Jul;7(3):170–174. PubMed PMID: 25395741; PubMed Central PMCID: PMCPMC4229791.
   Google Scholar
• Girum T, Wasie A. Return of fertility after discontinuation of contraception: a systematic review and meta-analysis. Contracept Reprod Med. 2018;3:9. PubMed PMID: 30062044; PubMed Central PMCID: PMCPMC6055351.
   Google Scholar
• Geukes M, van Aalst MP, Nauta MC, et al. The impact of menopausal symptoms on work ability. Menopause. 2012 Mar;19(3):278–282. PubMed PMID: 21997498.
   Google Scholar
• Al-Omari WR, Nassir UN, Izzat B. Estrogen ‘add-back’ and lipid profile during GnRH agonist (triptorelin) therapy. Int J Gynaecol Obstet. 2001 Jul;74(1):61–62. PubMed PMID: 11430944.
   Google Scholar
• Franke HR, van de Weijer PH, Pennings TM, et al. Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertil Steril. 2000 Sep;74(3):534–539. PubMed PMID: 10973651.
   Google Scholar
• Gallagher JS, Missmer SA, Hornstein MD, et al. Long-Term Effects of Gonadotropin-Releasing Hormone Agonists and Add-Back in Adolescent Endometriosis. J Pediatr Adolesc Gynecol. 2018 Aug;31(4):376–381. PubMed PMID: 29551430; PubMed Central PMCID: PMCPMC5997553.
   Google Scholar
• Revilla R, Revilla M, Hernandez ER, et al. Evidence that the loss of bone mass induced by GnRH agonists is not totally recovered. Maturitas. 1995 Sep;22(2):145–150. PubMed PMID: 8538483.
   Google Scholar
• Matsuo H. Prediction of the change in bone mineral density induced by gonadotropin-releasing hormone agonist treatment for endometriosis. Fertil Steril. 2004 Jan;81(1):149–153. PubMed PMID: 14711558.
   Google Scholar
• Sagsveen M, Farmer JE, Prentice A, et al. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev. 2003;(4):CD001297. DOI:10.1002/14651858.CD001297. PubMed PMID: 14583930; PubMed Central PMCID: PMCPMC7027701.
   Google Scholar
• Fogelman I. Gonadotropin-releasing hormone agonists and the skeleton. Fertil Steril. 1992 Apr;57(4):715–724. PubMed PMID: 1555680.
   Google Scholar
• Wu D, Hu M, Hong L, et al. Clinical efficacy of add-back therapy in treatment of endometriosis: a meta-analysis. Arch Gynecol Obstet. 2014 Sep;290(3):513–523. PubMed PMID: 24728145.
   Google Scholar
• Surrey ES. Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-back consensus working group. Fertil Steril. 1999;71(3):420‐424.
   Google Scholar
• Hornstein MD, Surrey ES, Weisberg GW, et al. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol. 1998 Jan;91(1):16–24. PubMed PMID: 9464714.
   Google Scholar
• Pierce SJ, Gazvani MR, Farquharson RG. Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up. Fertil Steril. 2000 Nov;74(5):964–968. PubMed PMID: 11056241.
   Google Scholar
• Filicori M, Cognigni GE, Arnone R, et al. Subcutaneous administration of a depot gonadotropin-releasing hormone agonist induces profound reproductive axis suppression in women. Fertil Steril. 1998 Mar;69(3):443–449. PubMed PMID: 9531874.
   Google Scholar
• Tse CY, Chow AM, Chan SC. Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study. Hong Kong Med J. 2000 Sep;6(3):260–264. PubMed PMID: 11025843.
   Google Scholar
• Tahara M, Matsuoka T, Yokoi T, et al. Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy (“draw-back” therapy). Fertil Steril. 2000 Apr;73(4):799–804. PubMed PMID: 10731543.
   Google Scholar
• Ferrero S, Barra F, Leone Roberti Maggiore U. Current and emerging therapeutics for the management of endometriosis. Drugs. 2018 Jul;78(10):995–1012. 10.1007/s40265-018-0928-0. PubMed PMID: 29946962.
   Google Scholar
• Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1992 Feb;166(2):740–745. PubMed PMID: 1536260.
   Google Scholar
• Hurst BS, Gardner SC, Tucker KE, et al. Delayed oral estradiol combined with leuprolide increases endometriosis-related pain. JSLS. 2000 Apr-Jun;4(2):97–101. PubMed PMID: 10917114; PubMed Central PMCID: PMCPMC3015370.
   Google Scholar
• Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The menopause study group. Am J Obstet Gynecol. 1994 May;170(5 Pt 1):1213–1223. PubMed PMID: 8178840.
   Google Scholar
• Marik JJ. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Obstet Gynecol. 1998 May;91(5 Pt 1):793–794. PubMed PMID: 9572232.
   Google Scholar
• Chu MC, Zhang X, Gentzschein E, et al. Formation of ethinyl estradiol in women during treatment with norethindrone acetate. J Clin Endocrinol Metab. 2007 Jun;92(6):2205–2207. PubMed PMID: 17341557.
   Google Scholar
• Vercellini P, Pietropaolo G, De Giorgi O, et al. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertil Steril. 2005 Nov;84(5):1375–1387. PubMed PMID: 16275232.
   Google Scholar
• Prentice A, Deary AJ, Goldbeck-Wood S, et al. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2000;(2):CD000346. DOI:10.1002/14651858.CD000346. PubMed PMID: 10796530.
   Google Scholar
• Pohl O, Marchand L, Fawkes N, et al. Gonadotropin-releasing hormone receptor antagonist mono- and combination therapy with estradiol/norethindrone acetate add-back: pharmacodynamics and safety of OBE2109. J Clin Endocrinol Metab. 2018 Feb 1;103(2):497–504. PubMed PMID: 29216361.
   Google Scholar
• Chwalisz K, Surrey E, Stanczyk FZ. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis. Reprod Sci. 2012;19(6):563‐571.
   Google Scholar
• Mäkäräinen L, Rönnberg L, Kauppila A. Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis. Fertil Steril. 1996 Jan;65(1):29–34. PMID: 8557151.
   Google Scholar
• Batzer FR. GnRH analogs: options for endometriosis-associated pain treatment. J Minim Invasive Gynecol. 2006 Nov-Dec;13(6):539–545. PubMed PMID: 17097577.
   Google Scholar
• Lee DY, Park HG, Yoon BK, et al. Effects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis. Obstet Gynecol Sci. 2016 Jan;59(1):32–38. PubMed PMID: 26866033; PubMed Central PMCID: PMCPMC4742473.
   Google Scholar
• DiVasta AD, Feldman HA, Sadler Gallagher J, et al. Hormonal add-back therapy for females treated with gonadotropin-releasing hormone agonist for endometriosis: a randomized controlled trial. Obstet Gynecol. 2015 Sep;126(3):617–627. PubMed PMID: 26181088; PubMed Central PMCID: PMCPMC4545413.
   Google Scholar
• Sadler Gallagher J, Feldman HA, Stokes NA, et al. The effects of gonadotropin-releasing hormone agonist combined with add-back therapy on quality of life for adolescents with endometriosis: a randomized controlled trial. J Pediatr Adolesc Gynecol. 2017 Apr;30(2):215–222. PubMed PMID: 26927501; PubMed Central PMCID: PMCPMC5001926.
   Google Scholar
• Lindsay XPC, Shaw RW, Bennink HJ, et al. The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl). Fertil Steril. 1996 Feb;65(2):342–348.
   Google Scholar
• Taskin O, Yalcinoglu AI, Kucuk S, et al. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. Fertil Steril. 1997;67(1):40‐45.
   Google Scholar
• Rebbeck TR, Troxel AB, Norman S, et al. A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. Int J Cancer. 2007 Apr 1;120(7):1523–1528. PubMed PMID: 17205521.
   Google Scholar
• Tanaka T. Effects of herbal medicines on menopausal symptoms induced by gonadotropin-releasing hormone agonist therapy. Clin Exp Obstet Gynecol. 2001;28(1):20–23. PubMed PMID: 11332582.
   Google Scholar
• Shams T, Firwana B, Habib F, et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med. 2014 Jan;29(1):204–213. PubMed PMID: 23888328; PubMed Central PMCID: PMCPMC3889979.
   Google Scholar
• Aisaka K. [Effectiveness of bisphosphonate administration during Gn-RH agonist therapy for endometriosis]. Nihon Rinsho. 2009 May;67(5):1027–1030. PubMed PMID: 19432128.
   Google Scholar
• Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc. 2009 Jul;84(7):632–7; quiz 638. PubMed PMID: 19567717; PubMed Central PMCID: PMCPMC2704135.
   Google Scholar
• French AE, Kaplan N, Lishner M, et al. Taking bisphosphonates during pregnancy. Can Fam Physician. 2003 Oct;49:1281–1282. PubMed PMID: 14594094; PubMed Central PMCID: PMCPMC2214129.
   Google Scholar
• Levy S, Fayez I, Taguchi N, et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone. 2009 Mar;44(3):428–430. PubMed PMID: 19059370.
   Google Scholar
• Cho YH, Um MJ, Kim SJ, et al. Raloxifene administration in women treated with long term gonadotropin-releasing hormone agonist for severe endometriosis: effects on bone mineral density. J Menopausal Med. 2016 Dec;22(3):174–179. PubMed PMID: 28119898; PubMed Central PMCID: PMCPMC5256355.
   Google Scholar
• Palomba S, Orio F Jr., Morelli M, et al. Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism. J Clin Endocrinol Metab. 2002 Oct;87(10):4476–4481. PubMed PMID: 12364422.
   Google Scholar
• Goldstein SR, Scheele WH, Rajagopalan SK, et al. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol. 2000 Jan;95(1):95–103. PubMed PMID: 10636510.
   Google Scholar
• Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol. 2004 Oct;104(4):837–844. PubMed PMID: 15458908.
   Google Scholar
• Grandi G, Mueller MD, Papadia A, et al. Inflammation influences steroid hormone receptors targeted by progestins in endometrial stromal cells from women with endometriosis. J Reprod Immunol. 2016 Sep;117:30–38. PubMed PMID: 27371899.
   Google Scholar
• McKinnon B, Mueller M, Montgomery G. Progesterone resistance in endometriosis: an acquired property? Trends Endocrinol Metab. 2018 Aug;29(8):535–548. . PubMed PMID: 29934050.
   Google Scholar
• Barra F, Ferrero S. Adhesion proteins: suitable therapeutic targets or biomarkers of therapy response for endometriosis? Acta Obstet Gynecol Scand. 2019 Jan 16. DOI:10.1111/aogs.13533. PubMed PMID: 30648260.
   Google Scholar
• Uemura T, Shirasu K, Katagiri N, et al. Low-dose GnRH agonist therapy for the management of endometriosis. J Obstet Gynaecol Res. 1999 Oct;25(5):295–301. PubMed PMID: 10533322.
   Google Scholar
• Kang JL, Wang XX, Nie ML, et al. Efficacy of gonadotropin-releasing hormone agonist and an extended-interval dosing regimen in the treatment of patients with adenomyosis and endometriosis. Gynecol Obstet Invest. 2010;69(2):73–77. PubMed PMID: 19923847.
   Google Scholar
• Alshehre SM, Duffy S, Jones G, et al. A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain. Reprod Biol Endocrinol. 2020 Apr 14;18(1):28.
   Google Scholar
• Barra F, Scala C, Ferrero S. Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain. Drugs Today (Barc). 2019 Apr;55(4):237–246. PubMed PMID: 31050692.
   Google Scholar
• Barra F, Seca M, Della Corte L, et al. Relugolix for the treatment of uterine fibroids. Drugs Today (Barc). 2019 Aug;55(8):503–512. PubMed PMID: 31461087.
   Google Scholar
• Gueuvoghlanian-Silva BY, Bellelis P, Barbeiro DF, et al. Treg and NK cells related cytokines are associated with deep rectosigmoid endometriosis and clinical symptoms related to the disease. J Reprod Immunol. 2018 Apr;126:32–38. PubMed PMID: 29477012.
   Google Scholar
• Donnez J, Taylor HS, Taylor RN, et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. Fertil Steril. 2020. DOI:10.1016/j.fertnstert.2020.02.114. S0015-0282(20)30244-2.
   Google Scholar